The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human IKK-alpha that contains serine 176 and serine 180.
Conjugate
Unconjugated
Form
Liquid
Purification
purified
Storage buffer
Dulbecco's PBS, pH 7.3, with 1mg/ml BSA
Preservative
0.05% sodium azide
Storage Conditions
-80°C
Tested Applications
Dilution *
ChIP assay (ChIP)
10µl
Flow Cytometry (Flow)
3-5 µg/million cells
Immunocytochemistry (ICC)
1 µg/ml
Immunofluorescence (IF)
1 µg/ml
Western Blot (WB)
0.1-1.0 ug/ml
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Background/Target Information
Nuclear factor kappa B (NF-kappa-B) is a ubiquitous transcription factor and an essential mediator of gene expression during activation of immune and inflammatory responses. NF-kappa-B mediates the expression of a great variety of genes in response to extracellular stimuli including IL-1, TNF-a and bacteria product LPS. NF-kappa-B is associated with Ikappa-B proteins in the cell cytoplasm, which inhibit NF-kappa-B activity. The long-sought Ikappa-B kinase (IKK), which phosphorylates Ikappa-B, and mediates Ikappa-B degradation and NF-kappa-B activation, was recently identified by several laboratories. IKK is a serine protein kinase, and the IKK complex contains alpha and beta subunits (IKK-a and IKK-b). IKK-a and IKK-b interact with each other and both are essential for the NF-kappa-B activation. IKK-a specifically phosphorylates Ikappa-B-alpha. IKK-a is expressed in a variety of human tissues.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
